Calmark announces updated launch plan
Calmark Sweden AB (publ) today announced an updated plan for its global launch of the product Calmark Neo-Bilirubin. The focus will be on the markets where distributor agreements have been signed, i.e. Southeast Asia, the Middle East, southern Europe and the Nordics. Certain countries in VIA Global's network will also be prioritized.
Calmark's board of directors announced today an updated launch plan for its product Neo-Bilirubin. The company will focus resources on the markets where distributor agreements have been signed and registrations are in progress or have been completed. This means that the priority countries for the launch are the following:
• Vietnam, Laos och Cambodia (MTTS)
• India (r2 Diagnostics)
• Saudi Arabia (Ajlan & Bros)
• Iraq and Egypt (Enox Pharma)
• Greece (Prime Biosciences)
• Italy (Prisma)
• Certain countries within VIA Global Health, still to be specified.
The sales organization of Calmark has limited human resources and capacity. It is of the utmost importance that the distributors who now have agreements, get the support and material they need to make a successful launch. Only when these distributors have progressed further in their sales work will Calmark expand the launch to more markets. Primarily, then, the distributors who already have contracts for parts of their sales area will get extended contracts to more countries. Secondly, more countries in Europe will be launched.
“Calmark's products are suitable for all markets worldwide. However, we choose to prioritize the markets where we already have good collaborations and see that launch and sales can take place in the near future,” says Anna Söderlund, CEO at Calmark. “In the last six months, we have attracted several major distributors in volume markets, something we are very happy about.”
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: